Eunice Nduati

Validation of high-throughput oxford nanopore technology for HIV-1 transmitted/founder virus identification.Byamukama, D. Ndekezi, C. Omara, D. Nakyanzi, A. Natwijuka, F. Kato, F. Mugaba, S. Kimuda, M. P. Kapaata, A. Nduati, E. Kaleebu, P. Balinda, S. N.
Int J Infect Dis, (2025). 161:108138

Advancing the course of HIV genomics research in Africa.Agamah, F. E. Arbuthnot, P. Tindana, P. Munung, N. S. Kasule, M. Ghansah, A. Mosepele, M. Gaolathe, T. Kekitiinwa, A. Nduati, E. Jumare, J. Gomez-Olive, F. X. Liebenberg, L. Dandara, C. Osawe, S. Julius, R. Muzambi, T. Natus, T. Omumbo, J. Mayne, E. Abimiku, A. Richardson, S. Matshaba, M. Skelton, M.
BMJ Glob Health, (2025). 10:

Unique genetic signatures in HIV-1 subtype A1 and A1D recombinant envelope glycoprotein distinguish contemporary transmitted/founder viruses from historical strains in East Africa.Kato, F. Kapaata, A. Galiwango, R. Nakyanzi, A. Ndekezi, C. Natwijuka, F. Omara, D. Obuku, A. E. Foley, B. Kaleebu, P. Nduati, E. Balinda, S. N.
Front Microbiol, (2025). 16:1632581

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.Chanda, C. Kibengo, F. Mutua, M. Ogada, F. Muturi-Kioi, V. Akis Yildirim, B. M. Amondi, M. Baines, A. Basajja, V. Borthwick, N. Bosire, K. Chambula, E. Chetty, P. Chinyenze, K. Chirro, O. Crook, A. De Bont, J. Fernandez, N. Ejou, P. Farah, B. Glaze, M. Gombe, B. Gumbe, A. Hayes, P. Itwi, S. Juma, S. Kabarambi, A. Kabengele, C. Kafeero, P. Kakande, A. Kanungi, J. Kidega, W. King, D. Mahira, R. Malogo, R. Matsoso, M. Michelo, C. Moyo, A. Mugaba, S. Mugenya, I. Muhumuza, P. Mujadidi, Y. F. Muriuki, M. Musale, V. Mutua, G. Muwowo, M. Mwale, F. Mwangi, I. Nakimbugwe, M. Namuyanja, A. Nduati, E. Nielsen, L. Nyange, J. Oino, G. Okech, B. Omosa-Manyonyi, G. Otieno, D. Palmer, S. Phiri, H. Ramko, K. Rutishauser, R. L. Sayeed, E. Sajabi, R. Serwanga, J. G. T. Wee E Wenden, C. Cicconi, P. Fast, P. Gilmour, J. Jaoko, W. Kaleebu, P. Kilembe, W. Kuipers, H. Sanders, E. J. Hanke, T.
Lancet Microbe, (2025). 6:101041

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.Lugano, D. Kutima, B. Kimani, M. Sigilai, A. Gitonga, J. Karani, A. Akech, D. Karia, B. Ziraba, A. K. Maina, A. Lambisia, A. Omuoyo, D. Mugo, D. Lucinde, R. Owuor, S. Konyino, G. Newman, J. Bailey, D. Nduati, E. Githinji, G. Agoti, C. N. Bejon, P. Scott, J. A. G. Agweyu, A. Kagucia, W. Warimwe, G. M. Sande, C. Ochola-Oyier, L. I. Nyagwange, J.
BMC Infect Dis, (2024). 24:1474

Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population.Stejskal, L. Thistlethwaite, A. Ramirez-Bencomo, F. Rashmi, S. Harrison, O. Feavers, I. M. Maiden, M. C. J. Jerse, A. Barnes, G. Chirro, O. Chemweno, J. Nduati, E. Cehovin, A. Tang, C. Sanders, E. J. Derrick, J. P.
Nat Commun, (2024). 15:6712

Exposure to common infections may shape basal immunity and potentially HIV-1 acquisition amongst a high-risk population in Coastal Kenya.Fwambah, L. Andisi, C. Streatfield, C. Bromell, R. Hare, J. Esbjornsson, J. Ndung'u, T. Sanders, E. J. Hassan, A. S. Nduati, E.
Front Immunol, (2024). 14:1283559

Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.Nyagwange, J. Kutima, B. Mwai, K. Karanja, H. K. Gitonga, J. N. Mugo, D. Sein, Y. Wright, D. Omuoyo, D. O. Nyiro, J. U. Tuju, J. Nokes, D. J. Agweyu, A. Bejon, P. Ochola-Oyier, L. I. Scott, J. A. G. Lambe, T. Nduati, E. Agoti, C. Warimwe, G. M.
Int J Infect Dis, (2023). 127:11-16

Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay.Fernandez, N. Hayes, P. Makinde, J. Hare, J. King, D. Xu, R. Rehawi, O. Mezzell, A. T. Kato, L. Mugaba, S. Serwanga, J. Chemweno, J. Nduati, E. Price, M. A. Osier, F. Ochsenbauer, C. Yue, L. Hunter, E. Gilmour, J. Iavi protocol C investigators
Front Immunol, (2022). 13:1029029

Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans.Sutton, H. J. Aye, R. Idris, A. H. Vistein, R. Nduati, E. Kai, O. Mwacharo, J. Li, X. Gao, X. Andrews, T. D. Koutsakos, M. Nguyen, T. H. O. Nekrasov, M. Milburn, P. Eltahla, A. Berry, A. A. Kc, N. Chakravarty, S. Sim, B. K. L. Wheatley, A. K. Kent, S. J. Hoffman, S. L. Lyke, K. E. Bejon, P. Luciani, F. Kedzierska, K. Seder, R. A. Ndungu, F. M. Cockburn, I. A.
Cell Rep, (2021). 34:108684

Symptom-based Scoring for Acute Human Immunodeficiency Virus.Sanders, E. J. Kigoro, A. Thiong'o, A. Nduati, E. Graham, S. M.
Clin Infect Dis, (2019). 69:736-737

Cytomegalovirus viraemia is associated with poor growth and T-cell activation with an increased burden in HIV-exposed uninfected infants.Garcia-Knight, M. A. Nduati, E. Hassan, A. S. Nkumama, I. Etyang, T. J. Hajj, N. J. Gambo, F. Odera, D. Berkley, J. A. Rowland-Jones, S. L. Urban, B.
AIDS, (2017). 31:1809-1818

Altered Memory T-Cell Responses to Bacillus Calmette-Guerin and Tetanus Toxoid Vaccination and Altered Cytokine Responses to Polyclonal Stimulation in HIV-Exposed Uninfected Kenyan Infants.Garcia-Knight, M. A. Nduati, E. Hassan, A. S. Gambo, F. Odera, D. Etyang, T. J. Hajj, N. J. Berkley, J. A. Urban, B. C. Rowland-Jones, S. L.
PLoS One, (2015). 10:e0143043

HIV-exposed uninfected children: a growing population with a vulnerable immune system?.Afran, L. Garcia Knight, M. Nduati, E. Urban, B. C. Heyderman, R. S. Rowland-Jones, S. L.
Clin Exp Immunol, (2014). 176:11-22

The plasma concentration of the B cell activating factor is increased in children with acute malaria.Nduati, E. Gwela, A. Karanja, H. Mugyenyi, C. Langhorne, J. Marsh, K. Urban, B. C.
J Infect Dis, (2011). 204:962-70

Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer.Nduati, E. Diriye, A. Ommeh, S. Mwai, L. Kiara, S. Masseno, V. Kokwaro, G. Nzila, A.
Parasitol Res, (2008). 102:1227-34

2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials.Nduati, E. Hunt, S. Kamau, E. M. Nzila, A.
Antimicrob Agents Chemother, (2005). 49:3652-7

Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?.Nzila, A. Ochong, E. Nduati, E. Gilbert, K. Winstanley, P. Ward, S. Marsh, K.
Trans R Soc Trop Med Hyg, (2005). 99:341-6

In vitro activities of 2,4-diaminoquinazoline and 2,4-diaminopteridine derivatives against Plasmodium falciparum.Ommeh, S. Nduati, E. Mberu, E. Kokwaro, G. Marsh, K. Rosowsky, A. Nzila, A.
Antimicrob Agents Chemother, (2004). 48:3711-4

Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance.Mberu, E. K. Nzila, A. M. Nduati, E. Ross, A. Monks, S. M. Kokwaro, G. O. Watkins, W. M. Hopkins Sibley, C.
Exp Parasitol, (2002). 101:90-6